Letter To The Editor
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2018; 10(12): 528-531
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.528
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
Yu Sunakawa, Hironaga Satake, Wataru Ichikawa
Yu Sunakawa, Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan
Hironaga Satake, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata-city, Osaka 573-1191, Japan
Wataru Ichikawa, Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa 227-8501, Japan
Author contributions: Sunakawa Y had full access to the data used in this study, drafted the paper, and had final responsibility for the decision to submit for publication; Sunakawa Y statistically analyzed the data; Satake H and Ichikawa W contributed to analysis and interpretation of the data; all authors contributed to the drafting or revision of the manuscript and have approved the final version.
Conflict-of-interest statement: Sunakawa Y has received honoraria from Taiho Pharmaceutical, Chugai Pharma, Yakult Honsha, Takeda, Merck Serono, Bayer Yakuhin, Eli Lilly Japan, and Sanofi; Satake H has received honoraria from Bayer, Chugai Pharma, Eli Lilly Japan, Merck Serono, Takeda, Taiho Pharmaceutical and Yakult Honsha; Ichikawa W has received honoraria from Chugai Pharma, Merck Serono, Takeda Pharmaceutical, and Taiho Pharmaceutical; research funding from Chugai Pharma, Takeda Pharmaceutical, and Taiho Pharmaceutical.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Yu Sunakawa, MD, PhD, Associate Professor, Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. y.suna0825@gmail.com
Telephone: +81-44-9778111 Fax: +81-44-9753755
Received: August 27, 2018
Peer-review started: August 27, 2018
First decision: September 11, 2018
Revised: September 17, 2018
Accepted: November 2, 2018
Article in press: November 2, 2018
Published online: December 15, 2018
Core Tip

Core tip: FOLFOXIRI plus bevacizumab regimen might be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC) regardless of RAS or BRAF status. However, subanalysis of a phase II trial of the triplet plus bevacizumab in patients with RAS mutant mCRC demonstrated that more patients with left-sided tumors achieved good tumor shrinkage and long duration of treatment than did patients with right-sided tumors, leading to higher rate of conversion to surgery in mCRC patients with left-sided tumors. Our data suggest that FOLFOXIRI plus bevacizumab may be a promising treatment for left-sided mCRC associated with RAS mutant tumors.